Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1a study of STSA-1002 in healthy subjects
NCT05166837Phase 1Completed
- Sponsor
- Staidson Biopharmaceutical
- Start
- Jan 2022
- Primary completion
- Jan 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of STSA-1002 in acute respiratory distress syndrome (ARDS) (5 cohorts), sponsored by Staidson Biopharmaceutical. Primary endpoints: Incidence of Adverse Events and Clinically Significant Abnormalities at 48 days, Maximum plasma concentration and 4 more. Started Jan 2022; status: completed.
02
Drugs
STSA-1002
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT05166837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05166837.